Long-term study of K-877 add-on to HMG-CoA reductase inhibitor in patients with dyslipidemia

Trial Profile

Long-term study of K-877 add-on to HMG-CoA reductase inhibitor in patients with dyslipidemia

Completed
Phase of Trial: Phase III

Latest Information Update: 23 May 2016

At a glance

  • Drugs Pemafibrate (Primary) ; HMG-CoA reductase inhibitors
  • Indications Dyslipidaemias
  • Focus Therapeutic Use
  • Sponsors Kowa
  • Most Recent Events

    • 08 May 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top